Advertisement
BMY vs PFE
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Bristol-Myers Squibb (BMY) has delivered stronger year-to-date and one-year total returns compared with Pfizer (PFE) amid a robust growth portfolio.
- Both companies raised 2026 revenue guidance following solid second-quarter results, with non-COVID or legacy portfolio momentum supporting performance.
- BMY trades at a lower trailing price-to-earnings ratio and offers a dividend yield near 4%, while PFE provides a higher yield above 6% with ongoing cost-reduction initiatives.
- Recent pipeline updates, including positive clinical data for BMY’s Sotyktu and PFE’s oncology and vaccine programs, have influenced market sentiment in recent weeks.
- BMY exhibits lower beta and more consistent recent momentum, whereas PFE benefits from a broader product base and announced productivity savings extending into 2029.
- Sector exposure remains similar in pharmaceuticals, with both firms navigating patent expirations through new launches and acquisitions.
Introduction
Bristol-Myers Squibb (BMY) and Pfizer (PFE) represent two established players in the pharmaceutical sector, each managing large portfolios of branded medicines while transitioning from legacy products facing patent expirations. Investors and traders focused on healthcare equities, dividend income, or relative sector performance often examine these names together because of their comparable market capitalizations, exposure to oncology and specialty therapeutics, and ongoing efforts to expand growth portfolios. This comparison highlights observable differences in recent price behavior, financial metrics, and pipeline developments to assist in evaluating positioning within the broader market environment.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) develops and commercializes medicines primarily in oncology, hematology, immunology, and cardiovascular disease. In recent market activity, the stock has shown resilience, posting year-to-date gains exceeding 20% and one-year returns near 45% despite a modest pullback over the past month. Second-quarter 2026 results featured revenue of approximately $13 billion, up 6% year over year, driven by a 15% increase in the growth portfolio that includes Opdivo, Reblozyl, and Camzyos. The company raised full-year revenue guidance to a range of $49 billion to $50 billion. Positive two-year data for Sotyktu in psoriatic arthritis and new regulatory progress, including accelerated approval for ZENBEXUS, have supported sentiment. Dividend announcements and pipeline advancements have contributed to a constructive tone in recent weeks.
PFE Overview and Recent Performance
Pfizer (PFE) focuses on vaccines, oncology, internal medicine, and rare diseases, with a significant legacy in infectious disease products. In recent market activity, shares have advanced roughly 17% year to date and 23% over the past year, though performance moderated with a slight decline over the trailing month. Second-quarter 2026 revenue reached $15 billion, reflecting operational growth in non-COVID products of 5% and an 18% increase in launched and acquired medicines. The company raised the midpoint of its 2026 revenue guidance to a range of $60.5 billion to $62.5 billion while expanding cost-saving targets. Pipeline developments, including positive Phase 3 results in oncology and updates on COVID-19 vaccine adaptations, alongside manufacturing and productivity initiatives, have shaped recent sentiment.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights select AI trading bots from a broader library of hundreds available across thousands of tickers. Only those demonstrating strong alignment with prevailing market conditions, consistent performance metrics, and suitable risk parameters earn placement in this focused listing. Available bots span diverse trading styles, timeframes, and ticker sets, with historical statistics covering win rates, drawdowns, and return profiles that vary widely by strategy. This selection process allows users to identify tools potentially relevant to current equity environments. Review the full collection on the Trending AI Robots page for detailed specifications.
Head-to-Head Comparison
Bristol-Myers Squibb (BMY) and Pfizer (PFE) both operate diversified pharmaceutical businesses but differ in portfolio composition and recent momentum. BMY derives a larger share of revenue from its growth portfolio, which has expanded faster than legacy products, while PFE emphasizes non-COVID growth through acquired assets and cost discipline. Valuation metrics show BMY trading at a lower trailing price-to-earnings multiple with moderate leverage, whereas PFE offers a higher dividend yield supported by a larger market capitalization. Recent price behavior favors BMY on a relative basis over the past year, though both stocks have benefited from earnings beats and guidance increases. Risk factors include patent cliffs for key products at each firm, offset by pipeline catalysts; BMY displays lower historical volatility, while PFE’s broader revenue base provides diversification. Market sentiment in recent weeks has reflected pipeline progress at both companies without clear dominance by either name.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative returns, and portfolio momentum in recent market activity, Tickeron’s AI models would currently assign a modestly higher probability of favorable positioning to Bristol-Myers Squibb (BMY) over Pfizer (PFE). Stronger year-to-date performance, a more pronounced contribution from growth assets, and lower beta support this probabilistic assessment, though outcomes remain dependent on upcoming catalysts and broader sector dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and PFE is a StrongBuy.
BMY | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 81 | 100 | |
SMR RATING 1..100 | 22 | 83 | |
PRICE GROWTH RATING 1..100 | 44 | 51 | |
P/E GROWTH RATING 1..100 | 66 | 5 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (20) in the Pharmaceuticals Major industry is in the same range as BMY (41). This means that PFE’s stock grew similarly to BMY’s over the last 12 months.
BMY's Profit vs Risk Rating (81) in the Pharmaceuticals Major industry is in the same range as PFE (100). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (83). This means that BMY’s stock grew somewhat faster than PFE’s over the last 12 months.
BMY's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as PFE (51). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (66). This means that PFE’s stock grew somewhat faster than BMY’s over the last 12 months.
| BMY | PFE | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 55% | 3 days ago 57% |
| Stochastic ODDS (%) | 3 days ago 59% | 3 days ago 51% |
| Momentum ODDS (%) | 3 days ago 56% | 3 days ago 44% |
| MACD ODDS (%) | 3 days ago 39% | 3 days ago 56% |
| TrendWeek ODDS (%) | 3 days ago 53% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 55% | 3 days ago 50% |
| Advances ODDS (%) | 3 days ago 56% | 3 days ago 54% |
| Declines ODDS (%) | 5 days ago 53% | 12 days ago 56% |
| BollingerBands ODDS (%) | 3 days ago 60% | 3 days ago 61% |
| Aroon ODDS (%) | 3 days ago 53% | 3 days ago 55% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 6 bearish.
- PFE’s TA Score: 4 bullish, 5 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -0.32% price change this week, while PFE (@Pharmaceuticals: Major) price change was +3.65% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.05%. For the same industry, the average monthly price growth was -5.35%, and the average quarterly price growth was +17.52%.
Reported Earning Dates
BMY is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.05% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with AMGN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +2.21% | ||
| AMGN - BMY | 57% Loosely correlated | +2.11% | ||
| PFE - BMY | 57% Loosely correlated | +0.92% | ||
| NVS - BMY | 55% Loosely correlated | +1.32% | ||
| GSK - BMY | 53% Loosely correlated | -0.83% | ||
| ABBV - BMY | 51% Loosely correlated | -0.29% | ||
More | ||||